Zhao [2013], has synthesized some thiadiazole derivatives. All newly synthesized et al. compounds were screened for their antimicrobial activity against Candida albicans, and methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, Staphylococcus (MRSA). Better results were obtained in screening for antimicrobial activity. Two aureus compounds, and were active against and MRSA at 50 per disc. 3 19, Staphylococcus aureus 𝜇g The minimum inhibitory concentration (MIC) for compound 3 toward S. was >50 aureus 𝜇g/mL, and toward MRSA was >50 as well. MIC of disulfide 19 toward was 50𝜇g/mL S. aureus 𝜇g/mL and toward MRSA was 25 𝜇g/mL. 3 19 Mendhe [2012], have prepared some substituted thiadiazole derivatives (IIIa, IIIb, IIIc and et al. IIId) which showed significant antimicrobial activity compared to the standard ciprofloxacin against and at 50, 100, 300 and 500 mcg/ml concentrations and to the standard E. coli S. aureus miconazole against at 50, 100, 300,500 mcg/ml concentrations. The 2-amino1, Candida albicans 3, 4-thiadiazole derivatives showed mild antibacterial activities and significant antifungal activities. Compounds IIIa IIIb IIIc IIId R H Cl Br NO2 Parimi [2012], have prepared a series of new 2-amino 1, 3, 4 thiadiazoles and 1, 3, 4- et al. followed by condensation with various substituted aldehydes to yield their Schiff bases. The synthesized compounds were assayed for their antimicrobial activity against two gram positive bacteria i.e. two gram negative bacteria Staphylococcus aureus, Bacillus subtilis, and two fungal species and Pseudomonas aeruginosa, Escherichia coli Aspergillus niger by agar well diffusion method. All the synthesized compounds showed good Trichoderma viride antimicrobial activity.
Zhao et al. [2013], has synthesized some thiadiazole derivatives. All newly synthesized compounds were screened for their antimicrobial activity against Candida albicans, Staphylococcus aureus, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus (MRSA). Better results were obtained in screening for antimicrobial activity. Two compounds, 3 and 19, were active against Staphylococcus aureus and MRSA at 50 𝜇g per disc. The minimum inhibitory concentration (MIC) for compound 3 toward S. aureus was >50 𝜇g/mL, and toward MRSA was >50 𝜇g/mL as well. MIC of disulfide 19 toward S. aureus was 50𝜇g/mL and toward MRSA was 25 𝜇g/mL. 3 19 Mendhe et al. [2012], have prepared some substituted thiadiazole derivatives (IIIa, IIIb, IIIc and IIId) which showed significant antimicrobial activity compared to the standard ciprofloxacin against E. coli and S. aureus at 50, 100, 300 and 500 mcg/ml concentrations and to the standard miconazole against Candida albicans at 50, 100, 300,500 mcg/ml concentrations. The 2-amino1, 3, 4-thiadiazole derivatives showed mild antibacterial activities and significant antifungal activities. Compounds IIIa IIIb IIIc IIId R H Cl Br NO2 Parimi et al. [2012], have prepared a series of new 2-amino 1, 3, 4 thiadiazoles and 1, 3, followed by condensation with various substituted aldehydes to yield their Schiff bases. The synthesized compounds were assayed for their antimicrobial activity against two gram positive bacteria i.e. Staphylococcus aureus, Bacillus subtilis, two gram negative bacteria Pseudomonas aeruginosa, Escherichia coli and two fungal species Aspergillus niger and Trichoderma viride by agar well diffusion method. All the synthesized compounds showed good antimicrobial activity. 4-